Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.
about
Perspectives for therapeutic HPV vaccine developmentLeveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicineMoving forward with human papillomavirus immunotherapies.Recent advances in understanding and preventing human papillomavirus-related disease.An overview of early investigational drugs for the treatment of human papilloma virus infection and associated dysplasia.Current state in the development of candidate therapeutic HPV vaccinesVirucide properties of cold atmospheric plasma for future clinical applications.The current state of therapeutic and T cell-based vaccines against human papillomaviruses.Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized medicine.Targeting Persistent Human Papillomavirus Infection.CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer.Therapeutic vaccines for high-risk HPV-associated diseases.Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteins.Targeting Head and Neck Cancer by Vaccination.Vaccinations for Anal Squamous Cancer: Current and Emerging Therapies
P2860
Q28069272-E7ECC14A-5251-4F72-80AF-B4BAF18332E3Q37224420-49C127F0-611A-4020-8643-276399095D0EQ37473299-A9938112-7D5A-46B7-9D31-D40F7B49504AQ37709706-17B5247E-3AA7-4A22-B8E5-E56954245710Q38386055-A866ED1F-E7D4-4AF6-B6B8-6BFF8CBCD84AQ38743922-02E9CE2B-D4EC-4805-978F-B3D4488AF88AQ38815371-C7B1CEBF-82EA-492A-9B16-E0CE5846F174Q39033576-22853329-189E-44AC-BBDF-1CAE6D52A552Q39044990-C4CBC4E3-4370-4007-A15B-61F06B25B116Q40078375-E9F981BF-F7BF-45C2-93C6-0B2321E25146Q41067857-BE031646-6A8B-4CD7-9EE9-17F271CF591AQ47255618-EB4481F5-F9BD-4479-9C02-79DC7A5DA46BQ47574658-FA4752EC-4F91-4C96-85DD-ED381A00B951Q54217605-D788469C-EB3D-4F25-90CD-53B11612CED7Q58548093-868EA0D4-46F8-4EA3-8713-9ED612DF5AC5
P2860
Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Regression of human papillomav ...... by MVA E2 therapeutic vaccine.
@ast
Regression of human papillomav ...... by MVA E2 therapeutic vaccine.
@en
Regression of human papillomav ...... by MVA E2 therapeutic vaccine.
@nl
type
label
Regression of human papillomav ...... by MVA E2 therapeutic vaccine.
@ast
Regression of human papillomav ...... by MVA E2 therapeutic vaccine.
@en
Regression of human papillomav ...... by MVA E2 therapeutic vaccine.
@nl
prefLabel
Regression of human papillomav ...... by MVA E2 therapeutic vaccine.
@ast
Regression of human papillomav ...... by MVA E2 therapeutic vaccine.
@en
Regression of human papillomav ...... by MVA E2 therapeutic vaccine.
@nl
P2093
P2860
P356
P1433
P1476
Regression of human papillomav ...... by MVA E2 therapeutic vaccine.
@en
P2093
Antonio Ricardez-Arenas
Armando Del Follo-Valencia
Carlos Rosales
Claudia Arellano-Fiore
Freddy Villarreal
Jose Martin Arroyo-Cazarez
Jose-Roberto Magallanes-Molina
Mario López-Contreras
Miguel Angel Pirez
Miriam Veronica Guerrero
P2860
P304
P356
10.1089/HUM.2014.024
P577
2014-12-01T00:00:00Z